Other conceptually distinct treatments for ACH are in clinical development, such as RBM-007, an RNA aptamer that neutralizes the cognate FGFR3 ligand fibroblast growth factor 2 (FGF2), and infigratinib, a pan-specific chemical inhibitor of FGFR1-3 catalytic activity.22 Here, FGFR3 is linked to achondroplasia.